Filing Flows

Filing Flows › 8-K events › Profound Medical

Profound Medical: entry into a material definitive agreement

Form 8-K filed Nov 3, 2026 · items 1.01, 7.01

FDA decisionsProfound Medical and Cook Medical’s iMRI Division Partner to Expand U.S. TULSA-PRO ® Sales Channels and Drive Recurring Revenue Growth

What the filing says

On October 28, 2026, Profound Medical (U.S.) Inc. (“Profound U.S.”), a wholly owned subsidiary of Profound Medical Corp. (the “Company” or “Profound”), entered into a Supply and Distribution Agreement (the “Agreement”) with Cook Medical Holdings LLC (“Cook”), effective as of October 23, 2026 (the “Effective Date”). Und

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Profound Medical at a glance

Latest quarterQ3 2026
Revenue$9.8M
Revenue Y/Y+86%
Operating margin-79.6%
IndustrySurgical & Medical Instruments & Apparatus

Profound Medical, Q3 2026: revenue $9.8M (+86% year over year), operating margin -79.6%. The chart follows the revenue to costs, profit and cash.

Profound Medical: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.